Which form of the minipill (progestin‑only oral contraceptive) is recommended?

Recommended Minipill Formulation

For most patients, drospirenone is the preferred progestin-only pill (POP) due to its superior ovulation inhibition and efficacy comparable to combined hormonal contraceptives, though norethindrone or norgestrel remain appropriate alternatives with simpler backup contraception requirements.

Primary Recommendation: Drospirenone POP

The 2024 CDC guidelines recognize drospirenone as a distinct category of minipill with different characteristics from traditional POPs 1. Key advantages include:

• Ovulation suppression: Drospirenone consistently inhibits ovulation, similar to combined oral contraceptives, providing superior contraceptive efficacy 2, 3
• Efficacy data: Studies show Pearl indices as low as 0.14-0.41 for desogestrel (similar mechanism to drospirenone), comparable to combined pills 2
• Recent evidence: A 2023 systematic review confirms newer formulations like drospirenone have significantly lower failure rates than traditional POPs 4

Important Caveat for Drospirenone

Drospirenone requires 7 days of backup contraception if started >1 day after menses begins, compared to only 2 days for traditional POPs 1. This longer window reflects its different mechanism of action.

Alternative: Norethindrone or Norgestrel POPs

Traditional POPs remain valid options, particularly when:

• Simpler backup contraception timing is preferred (only 2 days if started >5 days after menses) 1
• Cost or availability favors these formulations
• Patient has used them successfully before

Performance Characteristics

• Typical use efficacy: Median Pearl Index of 2.00 for traditional POPs (excluding newer formulations) 4
• Perfect use: Method failure rate around 1.05 4
• Mechanism: Work primarily through cervical mucus thickening rather than consistent ovulation inhibition

Clinical Decision Algorithm

1. First-line choice: Drospirenone POP for most patients seeking maximal efficacy

2. Consider traditional POPs (norethindrone/norgestrel) if:

   • Patient prefers shorter backup contraception window
   • Drospirenone unavailable or cost-prohibitive
   • Patient specifically requests traditional formulation

3. Special populations:

   • Lactating women: All POPs are appropriate; traditional formulations have extensive safety data in this population 5
   • Cardiovascular concerns: POPs are preferred over combined pills; traditional formulations have documented safety 6

Common Pitfalls

• Timing window confusion: The "3-hour window" guideline for traditional POPs may be overly conservative based on recent evidence 7, but remains the official recommendation
• Bleeding patterns: Expect irregular bleeding with all POPs; drospirenone may cause more bleeding variability but less overall bleeding 2
• Starting criteria: No examination needed before initiating any POP 1

The choice ultimately depends on balancing efficacy (favoring drospirenone) against practical considerations like backup contraception requirements and patient preference.